ImmunityBio IBRX 深 沪
等待开盘 09-30 09:30:00 美东时间
8.83
+0.310
+3.64%
华盛通- 最 高8.88
- 今 开8.52
- 成交量 836.60万股
- 最 低 8.52
- 昨 收 8.52
- 总市值 93.58亿
- 52周最高 12.43
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.95
- 委 比 -82.33%
- 总股本 10.60亿
- 历史最高 45.42
- 量 比 0.69
- 振 幅 4.23%
- 历史最低 0.93
- 每 手 1
- 风险率 2.62%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ImmunityBio’s New Sepsis Trial: Early-Stage Data With High-Stakes Market Potential
Immunitybio Inc ($IBRX) announced an update on their ongoing clinical study. Im...
09-26 00:30
美股牛股 | VKTX升近36%，给药频率减半仍维持97%减重；Vicor升逾19%，上调Q3营收指引
减肥药传来捷报！VKTX升近36%，给药频率减半仍维持97%减重；Vicor升逾19%，上调Q3营收指引；Grab Holdings升近9%，CEO增持近3000万美元股份>>
09-23 19:22
PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors
PDS Biotechnology Corporation completed an initial closing of its PIPE transaction, raising approximately $11.3 million. The round was led by Nant Capital, with additional participation from current investors. Proceeds will be used to repay debt and support clinical development, particularly advancing PDS0301 into late-stage trials for colorectal cancer. NantWorks founder Dr. Patrick Soon-Shiong joined the board, and Nant was granted an exclusive...
09-14 14:30
财报速睇 | ImmunityBio Inc 2026财年Q2营收0.51亿美元，同比增长93.9%；归母净利润亏损2.30亿美元，同比亏损扩大148.9%
华盛资讯8月4日讯，ImmunityBio Inc公布2026财年Q2业绩，公司Q2营收0.51亿美元，同比增长93.9%，归母净利润亏损2.30亿美元，同比亏损扩大148.9%。
08-04 20:04
财报速睇 | ImmunityBio Inc 2026财年Q2营收0.51亿美元，同比增长93.9%；归母净利润亏损2.30亿美元，同比亏损扩大148.9%
华盛资讯8月4日讯，ImmunityBio Inc公布2026财年Q2业绩，公司Q2营收0.51亿美元，同比增长93.9%，归母净利润亏损2.30亿美元，同比亏损扩大148.9%。
08-04 19:49
ImmunityBio Q2 Adj. EPS $(0.08) Beats $(0.09) Estimate, Sales $51.240M Beat $49.700M Estimate
ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 11.11 percent. This is a 20 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $51.240 million which...
08-04 19:41
ImmunityBio wins UAE approval for ANKTIVA cancer therapies
ImmunityBio ( ($IBRX) ) has shared an announcement. On July 29, 2026, ImmunityB...
07-31 05:51
ImmunityBio Achieves World's Broadest Bladder Cancer Approval as UAE Green Lights Lead Drug
The Emirates Drug Establishment (EDE) in the United Arab Emirates on Thursday approved ImmunityBio Inc.’s (NASDAQ:IBRX) immunotherapy drug, ANKTIVA. The regulatory action covers two distinct indications, making the UAE the fifth jurisdiction worldwide to approve the treatment and expanding its globa...
07-31 01:20
美股夜盘 | NUWELLIS涨91.01%，T3 Defense涨57.29%
Teladoc Health涨-19.39%；Advanced Biomed涨-18.12%；Meta Platforms涨-7.19%
07-30 08:05
Squeeze Watch: 10 Stocks Bears Love to Hate Most Right Now
Short‑interest screens are lighting up with a tight cluster of mid‑ and large‑cap names where bearish bets have gone all‑in, turning these stocks into live‑wire squeeze candidates rather than sleepy laggards. FIG stock is climbing. See the chart and price action here. A scan was run, using the Benzi...
07-14 02:29
